Adjuvant justification study of candidate malaria vaccines (257049), administered according to a 0, 1, 2 months schedule
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs GSK 257049 (Primary) ; AS01B; AS02
- Indications Falciparum malaria
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 23 Oct 2008 Actual start date changed from Apr 2007 to Mar 2007 as reported by ClinicalTrials.gov.
- 11 May 2008 Status changed from in progress to completed.